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Abstract
Background: Interferon-beta (IFNb) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action
are incompletely understood, individual treatment response varies, and biological markers predicting response to treatment
have yet to be identified.
Methods: The relationship between the molecular response to IFNb and treatment response was determined in 85 patients
using a longitudinal design in which treatment effect was categorized by brain magnetic resonance imaging as good
(n=70) or poor response (n=15). Molecular response was quantified using a customized cDNA macroarray assay for 166
IFN-regulated genes (IRGs).
Results: The molecular response to IFNb differed significantly between patients in the pattern and number of regulated
genes. The molecular response was strikingly stable for individuals for as long as 24 months, however, suggesting an
individual ‘IFN response fingerprint’. Unexpectedly, patients with poor response showed an exaggerated molecular
response. IRG induction ratios demonstrated an exaggerated molecular response at both the first and 6-month IFNb
injections.
Conclusion: MS patients exhibit individually unique but temporally stable biological responses to IFNb. Poor treatment
response is not explained by the duration of biological effects or the specific genes induced. Rather, individuals with poor
treatment response have a generally exaggerated biological response to type 1 IFN injections. We hypothesize that the
molecular response to type I IFN identifies a pathogenetically distinct subset of MS patients whose disease is driven in part
by innate immunity. The findings suggest a strategy for biologically based, rational use of IFNb for individual MS patients.
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Introduction
Interferon beta (IFNb) is routinely used to treat multiple
sclerosis (MS), and in randomized placebo-controlled trials,
reduced relapse rates by 30% [1–3]. However, clinical response
varied among individuals, and post-hoc analyses of one study
revealed that about 20% of IFNb recipients were poor responders
(PR), defined as $3 new T2 hyperintense brain lesions occurring
within 2 years of treatment onset [1,4]. Other studies by
independent groups [5–7] consistently demonstrate that new
brain MRI lesions develop in 20% to 25% of patients during IFNb
treatment and predict an unfavorable clinical outcome. Why some
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19262patients respond poorly to IFNb treatment, whereas others
respond better is not understood, and there are no validated
biomarkers that predict treatment response for individual patients.
IFNb (a type I IFN) treatment is therapeutic in MS patients, as
indicated by clinical trial patient group results. However, results
from a clinical trial of interferon gamma (IFNc) (a type II IFN)
[8,9] demonstrated disease activation in some patients. Because
type I and II IFNs regulate overlapping sets of IFN-regulated
genes (IRGs), it is possible that some patients may worsen with
IFNb treatment. Such an outcome would not be evident from
controlled clinical trials, where the majority of patients improve
with treatment. Type I IFN is a cardinal mediator of innate
immunity, whereas type II IFN participates in both innate and
adaptive immunity. In the IFNc trial, MS disease activation was
interpreted as implicating TH1-mediated processes in MS
pathogenesis. Development of type I IFN therapy continued,
however, leading to IFNb approval.
Increased bioavailability of type I IFNs is involved in diverse
autoimmune diseases [10], and increased expression of type I
IRGs has been detected in a subset of untreated MS patients [11],
suggesting that some patients have augmented innate immunity,
which is detected by monitoring type I IFN IRG expression in the
absence of IFNb injections. Moreover, several neuropathology and
immunology studies of IFNb treatment suggest that MS
immunopathogenesis may differ between patients [12,13]. There-
fore, it is plausible that most MS patients improve with IFNb
therapy, while a minority worsen.
Poor clinical response to IFNb can be related to production of
IFNb-neutralizing antibodies or to genetic variants in IFNb
receptors or signalling components [14]. In both categories,
patients have reduced IFNb bioavailability. However, such
patients account for a minority of PRs [15]. In the remaining
patients, poor response to IFNb might relate to the nature of the
IFNb response, a relationship that could yield insight to the
pathogenesis of MS, as well as strategies to personalize the use of
IFNb. Microarray-based cross-sectional expression analyses and
studies of individual candidate genes support this concept [16,17].
Here, we addressed the general hypothesis that the molecular
response to IFNb correlates with treatment response in individual
patients with MS, and thus might provide biological markers
useful to estimate prognosis, guide therapy, or offer insights into
pathogenesis.
Methods
Clinical Protocol
The Cleveland Clinic Institutional Review Board approved the
study. After discussion with our bioinformatics colleagues, but
without a formal power calculation, we sought to enroll 100
patients. All subjects provided written informed consent. Subjects
were eligible if they had clinically isolated syndrome (CIS) or
relapsing-remitting MS, were treatment-naı ¨ve, were initiating
intramuscular IFNb-1a treatment, and were followed at the
Mellen Center (our MS center). Each patient was examined at
baseline, 6, 12, and 24 months. At 3 and 18 months, patients were
contacted by phone to assess treatment compliance and ascertain
side effects. At baseline, 6, and 24 months, blood was collected for
IRG analysis in a clinical research unit immediately before and
exactly 12 hours after an IFNb injection, and the patients had
standardized brain MRI scans for quantitative assessment of
lesions and brain atrophy. At each visit, patients had neurological
exams to determine the Kurtzke Expanded Disability Scale Score
[18], the Multiple Sclerosis Functional Composite score [19], and
history of intercurrent relapses or illness; they also were given a
structured questionnaire to characterize flu-like symptoms, muscle
aches, chills, fatigue, headache, and loss of strength. Serum was
tested for IFN-neutralizing antibodies at 6 and 24 months. This
report focuses on the 85 subjects with complete data at baseline
and 6 months.
MRI Analysis
The MRI acquisition included T2-weighted fluid-attenuated
inversion recovery (FLAIR), T2- and proton density-weighted dual
echo fast spin echo, and T1-weighted spin echo images acquired
before and after injection of a standard dose of gadolinium
(0.1 mmol/kg). Images were analyzed using software developed
in-house to determine brain parenchymal fraction (BPF), T2 lesion
volume, gadolinium-enhancing lesion volume and number, and
the numbers of new and enlarging T2 lesions. BPF was calculated
from FLAIR images using fully automated segmentation software
[20]. Details of the lesion analysis methodology have been
previously described [21]. Briefly, T2 hyperintense lesions were
automatically segmented in the FLAIR and T2/PD images and
visually verified using interactive software to correct misclassifica-
tions. Six-month follow-up images were registered to baseline, and
intensity was normalized. Baseline T2 lesion masks were applied to
the registered 6-month images to identify persistent lesions. The
baseline images were then subtracted from the registered,
intensity-normalized 6-month images to automatically identify
new and enlarging T2 lesions at 6 months. For detecting enlarging
lesions, the registration and subtraction software has cut-offs based
on scan-rescan reproducibility of individual lesion volumes. For
lesions $ 150 mm
3, the lesion must grow by 20% to be counted as
enlarging. For lesions ,150 mm
3, the lesion must grow by 50% to
be counted as enlarging. New and enlarging T2 lesions were
visually verified using interactive software to generate the final
counts.
RNA isolation
RNA was extracted ex-vivo from blood using the PAXgene RNA
blood extraction kit (PreAnalytix, Switzerland) per the manufac-
turer’s instructions and concentrated by ethanol precipitation.
RNA quality and quantity were assessed by spectrophotometry
(absorbance ratios, 260/280 nm) and visualized by agarose gel
electrophoresis. Samples were stored at 280uC.
Genes analyzed by macroarray
The cDNA macroarray analysis was performed as previously
described [22,23]. IRGs on a custom macroarray were represent-
ed by 166 human cDNAs selected from the Unigene database.
Table S1 lists all genes on the macroarray with their GenBank
accession numbers. These type I IFN IRGs were identified by
microarray analysis of fibrosarcoma, epithelial, or endothelial cell
lines treated with IFN-a or IFNb [22,23]. All were known IRGs.
The protocol for spotting DNA on the membrane, probe
labeling, and hybridization has been described previously, with
modifications as follows [22,23]. Total RNA, 5 mg, isolated ex-vivo
from blood was used for generating radiolabeled cDNA probes by
reverse transcription with Superscript II in the presence of
32P-dCTP (Invitrogen, Carlsbad, CA). Residual RNA was
hydrolyzed by alkaline treatment at 70uC for 20 min after which
cDNA was purified using G50 columns (GE Healthcare,
Buckinghamshire, UK). Preparation of macroarrays and hybrid-
ization of radioactive cDNA were conducted as described
previously [22,23]. Induction ratios (IRs) were calculated from
radioactivity bound to the membranes.
To minimize variability, each patient’s samples at baseline and
6 months were processed in a single batch experiment. A detailed
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IRs were validated using real-time (rt) quantitative PCR for 5
genes: OASL (accession number NM003733); TRAIL (U37518);
IFI44 (D28915); HLADRA (J00194); and TIMP-1 (M59906).
Spearman correlation coefficients between IRs calculated from rt-
PCR and macroarray data for OASL, TRAIL, IFI44, HLADRA,
and TIMP-1 were 0.92, 0.75, 0.36, 0.72, and 0.54, respectively, all
statistically significant.
Statistical analysis
Poor response to IFNb was based on quantitative MRI analysis,
comparing the MRI at the 6-month visit with baseline. Poor
response was defined as the occurrence of $3 new or enlarging
lesions. Differences in baseline characteristics between good
responder (GR) and PR groups were compared using t-tests or
Fisher’s exact tests, as appropriate. A Poisson regression was used
to test group differences in the number of induced IRGs with
IRs$2.0 at the baseline injection. Pearson correlation coefficients
of log2 transformed IRs at initial injection compared with 6
months were computed for all 85 patients. Baseline, 6-month, and
24-month pair-wise correlations were computed for 5 randomly
selected patients from each group.
To minimize noise, a filter was applied to exclude IRGs that
were not regulated in this study. Genes with mean IRs within the
range of 0.9 to 1.1 (i.e., +/- 10% from an IR of 1.0, or no change)
were excluded. Using this method, 48 of the 166 IRGs were
eliminated from further analysis at the initial IFNb injection, and
30 IRGs were eliminated at the 6-month injection. For the
remaining IRGs, covariate-adjusted least-square means (LS
means) of the log2-transformed IRs were computed and compared
between response groups by ANCOVA. The covariates were
baseline age, sex, presence of gadolinium-enhancing lesions, and
T2 volume.
The remaining IRGs were classified as upregulated or
downregulated as follows: an IRG was upregulated if more than
50% of the 85 subjects had an IR.1.0; an IRG was classified as
downregulated if more than 50% had an IR,1.0. For each IRG,
LS means of the IRs were compared between PRs and GRs. The
response was classified as exaggerated at the group level if
PRs.GRs in upregulated genes, or PRs,GRs in downregulated
genes. The proportion of genes showing an exaggerated response
in PRs was tested (one-sided) with a binomial proportion test
assuming a null hypothesis of proportion#0.5.
To further investigate whether IRGs could discriminate
between the responder groups, the magnitude of the exaggeration
in each patient was computed as a sum of the exaggerated
amounts (absolute differences between individual IRs and IR
medians) for each regulated IRG. That is, for upregulated genes, if
the individual IR was greater than the median for the whole
group, or for downregulated genes, if the individual IR was less
than the median for the whole group, then the exaggerated
amount was calculated. The magnitudes of exaggerated responses
were compared in PRs and GRs at the first and 6-month injections
using ANCOVA with baseline demographic features, presence of
baseline gadolinium lesions, and baseline T2 lesion volume as
covariates.
Results
Research Subjects
Of the 99 subjects enrolled, 85 continued to take intramuscular
IFNb-1a for at least 6 months, which was the predetermined time-
point for determining treatment response based on MRI, for
correlation with IRG macroarray results. Reasons for drop out
included: side effects (n=4); new health issues (n=2); no
explanation provided (n=4); left area (n=1); switched to
glatiramer acetate per patient preference (n=1); sample hybrid-
ization not adequate at baseline or 6 month injection (n=2).
Subjects were encouraged to remain in the protocol for 24 months,
so that the relationship between 6-month MRI activity and later
disease progression, as well as stability of the IFNb molecular
response, could also be determined. At the time of this report,
subject accrual was complete, and all subjects had 6-month visits.
This report focuses on the analysis of 85 patients with complete
data at baseline and 6 months. Of the 14 patients who were
enrolled in the study but did not complete the planned 6-month
macroarray analysis, 12 discontinued IFNb-1a, whereas sample
hybridization was unsuccessful in the other 2, either at first
injection or 6 months. Ten patients who had completed the 24-
Table 1. Comparison of baseline characteristics between patients with a good vs poor response to IFNb treatment.*
Characteristic Good Responders (n=70) Poor Responders (n=15) All Patients (n=85) P-value GR vs PR
Age (years) 36.3 (9.4) 33.0 (11.2) 35.7 (9.8) 0.30
Symptom duration (years) 2.5 (3.0) 1.2 (1.7) 2.4 (2.9) 0.39
Female (%) 69 47 65 0.11
White (%) 93 80 91 0.14
CIS /RRMS (%/%) 34 / 66 20 / 80 32 / 68 0.37
EDSS 1.6 (1.0) 1.6 (1.2) 1.6 (1.0) 0.91
MSFC score 0.39 (0.48) 0.19 (0.41) 0.35 (0.47) 0.10
Patients (%) with gad-enhancing lesions 24.3 53.3 29.4 0.03
Gad-enhancing lesion volume (mm
3) 0.097(0.38) 0.44 (0.72) 0.16 (0.47) 0.09
T2 Volume 3.0 (3.7) 5.8 (3.9) 3.5 (3.8) 0.02
T1 BH Volume 0.55 (0.75) 0.87 (0.82) 0.61 (0.77) 0.19
BPF 0.858 (0.014) 0.859 (0.013) 0.859 (0.014) 0.79
*All values are mean6SD, unless otherwise indicated.
CIS=clinically isolated syndrome; RRMS=relapsing-remitting multiple sclerosis; EDSS=Expanded Disability Scale Score; MSFC=Multiple Sclerosis Functional
Composite; Gad=gadolinium; BH=black hole; BPF=brain parenchymal fraction.
doi:10.1371/journal.pone.0019262.t001
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Baseline demographic and disease characteristics did not signifi-
cantly differ between those who completed the first 6 months and
those who did not (data not shown). For all other analyses, only the
85 patients who completed the first 6 months were included.
Among these 85, 32% had CIS with multiple brain MRI lesions,
and 68% had relapsing-remitting MS. The mean age was 35.7
years; mean disease duration was 2.4 years; 65% were women; and
91% were white. At 6 months, 15 (18%) subjects were classified as
PRs based on our pre-determined MRI definition. The two groups
were similar at baseline on all characteristics except that a higher
proportion of PRs had gadolinium-enhancing lesions and greater
T2 lesion volumes at baseline, indicating PRs had more severe
disease (Table 1).
IRG Response to First Injection and Stability over Time
Preliminary assays in healthy subjects not receiving IFNb
showed that IRs did not vary more than 1.5-fold in assays
separated by 12 or 24 hours. Therefore, an IR$2.0 defined
induction of an IRG. The number of induced IRGs at the first
IFNb injection varied among patients, ranging from 7 to 135, with
no relationship between IFNb responder status and number of
induced genes (p=0.76) (data not shown). Similarly, the pattern of
response to the initial IFNb injection varied considerably between
patients as previously reported
22.
Figure 1 shows the IRs at first injection plotted against IRs at 6
months for a representative patient with a good response (Fig 1A),
a representative patient with a poor response (Fig 1B), for all 70
patients with a good response (Fig 1C) and for all 15 patients with
a poor response (Fig 1D). Despite inter-individual variability in the
pattern and magnitude of IRG response after the first IFNb-1a
injection, the response was remarkably stable over time for
individual subjects. Figure S1 shows the IRs at baseline and 6
months for each of the 85 patients. Two subjects (patients 7 and
25) had viral infections at the initial injection and so had little or
no IRG induction at the first injection due to high pre-injection
IRG expression levels. Both subjects responded to IFNb injection
at 6 months. Patient 21 developed neutralizing antibodies to IFNb
detected at 6 months. This subject responded briskly to the first
IFNb injection, but minimally at 6 months. Neutralizing antibody
testing of all other subjects was negative at 6 months.
Excluding those three subjects, IRs at first injection strongly
correlated with IRs at 6 months for individual patients [Pearson
correlation coefficient mean (6SD)=0.8160.11]. The mean
correlation coefficient for the 15 PRs (study numbers 1, 4, 12,
14, 18, 40, 49, 57, 62, 65, 66, 70, 87, 91, and 92) was 0.8160.10,
Figure 1. Correlations between induction ratios (IRs) for two patients at the initial (baseline) and 6-month injections. A) Patient 2 had
a good treatment response; B) Patient 1 had a poor treatment response; C) All genes in all patients with a good treatment response; and D) All genes
in all patients with a poor treatment response. Identical IRs at the two time points fall on the diagonal line whereas deviation from the diagonal
reflects changes in the IRs at the first injection compared with the 6-month injection. Note the highly conserved IRG response at the two time points,
both at the initial injection and 6 months later. There were no differences in consistency of the response in the good vs poor responders.
Supplemental Figure 1 shows correlations for each of the 85 patients, including patients 1 and 2.
doi:10.1371/journal.pone.0019262.g001
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(excluding subjects 7, 21, and 25, Figure S1).
The IRG analysis was repeated at 24 months for 10 selected
patients (5 PRs and 5 GRs) (Figure 2). The IRG response was
consistent over 2 years, with no appreciable difference between
GRs and PRs. The IRs strongly correlated between baseline and 6
months (r=0.80 for GRs, r=0.91 for PRs); between 6 months and
24 months (r=0.81 for GRs, r=0.83 for PRs); and between
baseline and 24 months (r=0.83 for GRs, r=0.87 for PRs). Figure
S2 shows scatter plots for each patient, demonstrating highly
consistent molecular responses to IFNb injections over 24 months,
regardless of responder status. These results suggested that
treatment response status could not be attributed to attenuation
of the molecular response to IFNb over time.
IRG Response in Good vs Poor IFNb Responders
The biological effects of IFNb are traditionally accounted for by
the activities of the IRG protein products [24]. We addressed
Figure 2. Scatter plots showing correlations between induction ratios between 3 time points over 24 months. Panels (A), (C) and (E): 5
good responders showing the correlation between the initial injection and the 6-month injection (A); between the 6-month and 24-month injection
(C); and between the initial and the 24-month injection (E). Panels (B), (D), (F): 5 poor responders at the same time points. Note the highly conserved
IRG response over 24 months, both in the good and poor responders.
doi:10.1371/journal.pone.0019262.g002
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might explain PR status, either by revealing induction of
deleterious inflammatory gene products [17] or selective failure
of expression of beneficial genes [25]. In univariate analyses of the
genes remaining after filtering, the covariate-adjusted LS mean
IRs indicated differential responses (p#0.05) between the PR and
GR groups for 13 genes at the initial IFNb injection, and 16 genes
at the 6-month injection (Table 2). Unexpectedly, for all 13 genes
at the initial injection, and for all 16 genes at the 6-month
injection, the response, either induction or repression, was greater
for patients with a poor response. This suggested an exaggerated
IFNb molecular response in the patients with a poor clinical
response to IFNb treatment. Figure 3 shows that 97 (82%) of 118
genes with mean IRs outside the 0.9–1.1 range showed an
exaggerated response to IFNb at the first injection, and 100 (74%)
of 136 genes with mean IRs outside the 0.9–1.1 range showed an
exaggerated response at the 6-month injection. The proportion of
genes with an exaggerated response in PRs was significantly higher
than 50% (p,0.001 at first injection and 6 months). Figure 4
shows the magnitude of the difference between the biological
response for GRs and PRs at the first injection (figure 4A) and at 6
months (Figure 4B). the magnitude of exaggeration was signifi-
cantly higher in PRs at the first injection (p=0.007 and 6-month
injection (p=0.02).
Discussion
Although IFNb is the most commonly used disease-modifying
treatment for MS, its mechanisms of action are not fully
understood, no biological markers are available to guide
individualized therapy, and differential clinical responsiveness is
not understood at a mechanistic level. We sought to determine
molecular correlates of the treatment response to IFNb therapy in
relapsing-remitting MS. Response to IFNb was defined in
advance, using MRI to classify treatment response in individual
patients. In that regard, numerous reports have documented that
patients developing new lesions while on IFNb have relatively poor
clinical outcomes. [4–7] Neutralizing antibodies were not observed
at 6 months in any of the 15 patients classified as poor responders,
and so could not have explained the poor response to therapy. We
believe these 15 patients will have a poor clinical outcome
compared with the patients classified as a good treatment
response, but that differences will become evident only with
longer follow-up. We continue to follow these patients, and will
report outcomes in a future publication after all patients have been
followed at least 2 years.
We initially hypothesized that 1) the molecular response to
IFNb would differ between patients but would be stable over time
within individuals, and 2) treatment response would correlate with
the nature of the primary molecular response or its persistence
over time. We confirmed that the molecular response differs
significantly between patients in regard to the identity and number
of regulated IRGs and the extent of induction or repression.[22]
Our study documents that the IRG response was remarkably
consistent in individual MS patients for as long as 24 months,
suggesting an individual IRG ‘fingerprint’. Exceptions to this
finding (patients 7, 21, 25) were uncommon and readily explained.
The molecular response remained consistent over time regardless
of MRI outcome, excluding the possibility that attenuated IRG
Table 2. Univariate analysis with adjustment for covariates
comparing induction ratios between good and poor
responders to IFNb.
Time of IFNb
Injection Gene Mean Adjusted IR P Value
Good
Response
Poor
Response
Month 0 IL2 0.89 0.47 0.001
(n=85) ISG15-L 2.01 3.07 0.004
TIMP-1 0.96 0.65 0.005
IDO 3.18 5.17 0.008
CD3e 0.73 0.54 0.012
IFIT5 1.91 2.51 0.013
FK506 1.29 1.65 0.013
P4Ha1 1.14 1.41 0.020
PI3K 1.50 1.99 0.026
OASL 3.41 4.63 0.030
HLADP 0.91 0.72 0.039
TRAIL 4.50 6.23 0.048
MT1X 2.95 4.53 0.049
Month 6 IFIT5 1.53 2.25 0.001
(n=84)* Elastase2 1.16 1.45 0.003
CCR5 1.09 1.40 0.004
UBE2L6 1.56 2.09 0.011
Hou 1.54 2.35 0.016
TRAIL 3.51 4.93 0.028
TNFAIP6 2.17 3.05 0.029
IL 15 1.28 1.64 0.030
TOR1B 1.96 2.57 0.033
IP-10 1.20 1.49 0.039
Caspase 1 1.36 1.80 0.039
FLJ20035 1.67 2.19 0.040
PLSCR1 1.22 1.46 0.040
IFN-44 2.00 2.68 0.043
CEACAM 1.52 1.96 0.045
RIG-1 3.27 4.60 0.045
IR=Induction ratio.
*1 patient with NAB with no biological response at 6 months was excluded.
doi:10.1371/journal.pone.0019262.t002
Figure 3. Number of genes with an exaggerated response in
poor responders at the initial (A) and 6-month injection (B). The
dark gray bars represent genes with an exaggerated response, and the
light gray bars represent genes with no exaggerated response, as
defined in the Methods section. The proportion of genes with an
exaggerated response in PRs was significantly higher than 50% at first
injection (p,0.001) and 6 months (p,0.001).
doi:10.1371/journal.pone.0019262.g003
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differed, however, in the magnitude of IRG induction and
repression, both of which, surprisingly, were exaggerated in PRs.
This study differs methodologically from prior studies of IRG
expression in MS. First, we used a prospective design and a
defined, validated outcome measure based on an objective MRI
criterion [4] that clearly delineates patients with poor clinical
outcomes on IFNb treatment [7]. Second, we quantified IRG
expression with a customized cDNA macroarray assay containing
166 IRGs, selected on the basis of previous microarray
experiments. This macroarray has been validated for other disease
indications such as IFN-a treatment for hepatitis C virus, and is
reproducible, sensitive, and quantitative [23]. For focused
quantitative studies of a relatively small number of regulated
genes such as the IRGs, the macroarray was well-suited to our
research questions. Importantly, phlebotomy was performed in a
clinical research unit precisely 12 hours after IFN injection,
minimizing variability induced by differences in sampling times.
Figure 4. The magnitude of the exaggerated response for good and poor responder groups at the initial (A) and the 6-month (B)
injection. The magnitude of exaggeration was significantly higher in PRs at the first (p=0.007) and 6-month injections (p=0.02).
doi:10.1371/journal.pone.0019262.g004
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the molecular response measure. The findings can be extrapolated
to IFNb treatment generally because the molecular response to the
three approved IFNb preparations is highly consistent [26–30].
The consistent pattern of exaggerated induction or repression of
IRGs in patients who responded poorly was observed at the initial
IFNb injection and confirmed at 6 months, indicating that this
exaggerated response was a stable phenotype. Over time,
circulating leukocyte subsets change with IFNb therapy, so it
was not surprising that the specific genes identified as distinguish-
ing good and poor responders differed at the two time points. This
observation leads to a novel hypothesis: patients with MS who
exhibit an exaggerated response to exogenous IFNb have both a
poor treatment response and more severe disease. Indeed, patients
categorized as poor responders were more likely to have
gadolinium enhancing lesions at baseline, and had a higher T2
lesion burden. Thus, patients with poor response to IFNb
injections already had more active disease at treatment start. We
believe the explanation for this observation is that the response to
exogenous IFNb injections reflects responses to endogenous type 1
IFN. It has been well recognized that some, but not all, MS
patients experience relapses during viral infection, which strongly
induces endogenous type 1 IFN. An exaggerated response to type
1 IFN plus disease driven by aberrant innate immunity might
explain the response to viral infection in a subset of MS patients.
Our hypothesis would predict that patients experiencing disease
activation with viral infections would have more severe disease.
This has not been studied.
Our study has several limitations. First, there was no placebo-
treated, or untreated comparison group, so the subset we’ve
identified could simply represent more severe disease, and the
outcome might have nothing to do with IFNb treatment. Second,
advances in microarray technology during the course of this
longitudinal study now permit more quantitative assessment of the
RNA we collected. Those experiments, currently ongoing, have
the potential to confirm or refute the current findings, and possibly
to extend them considerably. Third, the classification of poor
treatment response was based entirely on a prospectively defined
MRI outcome. The clinical outcome for poor and good response
subgroups needs to be established in long-term follow-up studies,
which are ongoing. Lastly, our findings must be confirmed in
separate patient cohorts and by independent investigators.
Our hypothesis is consistent with a recent report by Axtell and
colleagues suggesting that fundamentally different pathogenic
pathways in MS subjects underlie the differential response to IFNb
therapy [12]. They reported that IFNb was effective in suppressing
murine experimental allergic encephalomyelitis caused by transfer
of TH1 cells, but exacerbated disease caused by transfer of TH17
cells. Intriguingly, two IRGs we found to be markedly regulated by
IFNb (IL2, PI3K) would be predicted to act in a manner consistent
with the hypothesis proposed by Axtell et al. Specifically, we
observed exaggerated inhibition of IL2 and exaggerated induction
of PI3K, which together could cause TH17-mediated inflamma-
tion that would be resistant to inhibition by gene products of the
type I IFN response, including IL10 [31,32]. van Baarsen et al.
[33] found that high expression of 15 IRGs before starting IFNb
treatment predicted limited induction of IRGs after treatment.
They concluded that the ability to respond to IFNb pharmaco-
logically was intrinsic to circulating blood cells, before the
introduction of IFNb. Our results are in part consistent with
Comabella et al., [34] who found overexpression of IFN-induced
genes prior to IFNb treatment in patients with a poor clinical
response. Our findings also generally agree with recent genome-
wide association studies showing that MS susceptibility was
associated with a SNP near the IRF8 gene [35] and another
SNP within the gene encoding TYK2 [36], a cytoplasmic tyrosine
kinase required for IFN responses. The IRF8 susceptibility SNP
was associated with increased expression of a wide variety of IFN
pathway genes, and the TYK2 SNP encoded a variant amino acid
in the kinase domain that was predicted to modify IFN-driven
gene expression. These observations suggest that the type I IFN
pathway, a critical component of the innate immune system, may
play a pathogenic role in some patients with MS. Finally, our
results are reminiscent of findings related to the IFN-treatment
response in patients with chronic hepatitis C infection [37].
Patients with a poor treatment response to pegylated IFNa and
ribavirin had high levels of IRG products in pre-treatment liver
biopsies compared to patients with a good response, suggesting
that activation of the endogenous IFN system was not only
ineffective in clearing hepatitis C virus, but was also predictive of a
poor response to exogenous IFN therapy.
Despite these recent reports, predictive biomarkers for IFNb
treatment failure have not been identified or validated
[6,14,16,38–48]. Our observations introduce the novel concept
that the differential treatment response to IFNb is not explained by
a specific set of IRGs, but rather by a generally augmented IRG
response to IFNb injections, and that response to IFNb injection
unmasks a subset of patients who not only respond poorly to IFNb
treatment, but who have a pathogenetically distinct form of MS.
This hypothesis has at least two major implications. First, because
the response to an initial IFNb injection strongly correlated to
response to therapy 6 months later it should be possible to develop
assays that identify patients who will have a poor response to IFNb
therapy, enabling the tailoring of disease-modifying therapy for
individual patients. It may be possible to develop an assay that
could be applied to decide whether a patient is likely to do poorly
on IFNb therapy. Because MS lesions can irreversibly injure axons
[49], optimizing therapy quickly might substantially benefit
patients. Development and validation of a biomarker based on
these observations, is beyond the scope of this initial report,
however.
A more wide-ranging implication relates to MS pathogenesis.
Mechanistic proposals for disease pathogenesis have focused on
adaptive immunity, particularly immune responses directed
against myelin constituents. We found that IFNb recipients who
became PRs already had higher levels of disease activity and
disease burden, as measured by MRI, upon entering the study. We
hypothesize that these patients exhibit a pathogenic pathway that is
characterized in part by their response to endogenous type 1 interferon.A
corollary is that differences in innate immunity, either within type
I IFN pathways or affecting the expression levels of IRGs
indirectly, are determinant for enhanced disease severity in PRs.
In that regard, IFNb injection can be viewed as a provocative
test that may expose a genetically or epigenetically determined
type 1 IFN response that contributes to pathogenesis. In these
individuals, exogenous IFNb elicits an exaggerated response,
either by upregulation from a lower pre-injection IRG expression
level
32 or through augmented responses from an equivalent pre-
injection baseline. In either case, the findings in this study
implicate innate immunity in MS pathogenesis from its onset and
may provide novel insights into the fundamental disease process,
along with new therapeutic targets and hope for personalized use
of IFNb.
Supporting Information
Figure S1A Scatter plots showing the IFNb molecular
response at baseline and 6 months for 57 of 85 patients.
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baseline is shown on the x-axis and at 6 months is shown on the y-
axis. For each subject, the induction ratio for each of 166 genes is
shown at the two time points. The variability of the molecular
response between the two time points is indicated by deviation
from the diagonal line in each plot. A consistent response at the
two time points is evident except for patients 7, 21, and 25 (see
text). Also, response consistency was similar between patients with
poor treatment response (circled study subject numbers).
(EPS)
Figure S1B Scatter plots showing the IFNb molecular
response at baseline and 6 months for the remaining 37
of the 85 patients. The study subject number is indicated above
each plot; response at baseline is shown on the x-axis and at 6
months is shown on the y-axis. For each subject, the induction
ratio for each of 166 genes is shown at the two time points. The
variability of the molecular response between the two time points
is indicated by deviation from the diagonal line in each plot.
Response consistency was similar between patients with poor
treatment response (circled study subject numbers).
(EPS)
Figure S2 Scatter plots for 10 individual patients
showing a consistent response over 24 months. Five good
and 5 poor responders were randomly selected from each group
with macroarray data at baseline, 6 months, and 24 months. The
first 3 columns show patients with a good treatment response, and
the last 3 columns are patients with a poor treatment response.
Columns 1 and 4 compare responses at baseline and 6 months;
columns 2 and 5 compare responses at 6 and 24 months; and
columns 3 and 6 compare responses at baseline at 24 months.
Note the consistency of response for all time points and that the
molecular response is consistent regardless of whether treatment
response is good or poor.
(EPS)
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